Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome
Authors:
- Janine BüttnerJBJanine Büttner
- Elisabeth BlüthnerEBElisabeth Blüthner
- Sophie GreifSGSophie Greif
- Anja KühlAKAnja Kühl
- Sefer ElezkurtajSESefer Elezkurtaj
- Jan UlrichJUJan Ulrich
- Sebastian MaasbergSMSebastian Maasberg
- Christoph JochumCJChristoph Jochum
- Frank TackeFrank Tacke
- Ulrich-Frank PapeUPUlrich-Frank Pape
Open Access
- 29 September 2023
- Vol. 15 (19) , 4220
Abstract
Introduction: The human intestinal tract reacts to extensive resection with spontaneous intestinal adaptation. We analyzed whether gene expression analyses or intestinal permeability (IP) testing could provide biomarkers to describe regulation mechanisms in the intestinal barrier in short bowel syndrome (SBS) patients during adaptive response or treatment with the glucagon-like peptide-2 analog teduglutide. Methods: Relevant regions of the GLP-2 receptor gene were sequenced. Gene expression analyses and immunohistochemistry were performed from mucosal biopsies. IP was assessed using a carbohydrate oral ingestion test. Results: The study includes 59 SBS patients and 19 controls. Increases in gene expression with teduglutide were received for sucrase-isomaltase, sodium/glucose cotransporter 1, and calcium/calmodulin serine protein kinase. Mannitol recovery was decreased in SBS but elevated with teduglutide (Δ 40%), showed a positive correlation with remnant small bowel and an inverse correlation with parenteral support. Conclusions: Biomarkers predicting clinical and functional features in human SBS are very limited. Altered specific gene expression was shown for genes involved in nutrient transport but not for genes controlling tight junctions. However, mannitol recovery proved useful in describing the absorptive capacity of the gut during adaptation and treatment with teduglutide.Keywords
Funding Information
- Shire Investigator Initiated Research Program (IIR-DE-002562, 130208)
- Zealand Pharma Denmark (IIR-DE-002562, 130208)
- Forschungsförderung of the Charité (IIR-DE-002562, 130208)
This publication has 113 references indexed in Scilit:
- The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibodyDiagnostic Pathology, 2012
- Emerging treatment options for short bowel syndrome: potential role of teduglutideClinical and Experimental Gastroenterology, 2011
- Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndromeGut, 2011
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family membersDiabetes Therapy, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- CASK Deletion in Intestinal Epithelia Causes Mislocalization of LIN7C and the DLG1/Scrib Polarity Complex without Affecting Cell PolarityMolecular Biology of the Cell, 2009
- Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1Proceedings of the National Academy of Sciences, 2009
- Carbohydrate/fat ratio in the diet alters histone acetylation on the sucrase–isomaltase gene and its expression in mouse small intestineBiochemical and Biophysical Research Communications, 2007
- Almost all about citrulline in mammalsAmino Acids, 2005
- Genetic basis for increased intestinal permeability in families with Crohn’s disease: role of CARD15 3020insC mutation?Gut, 2005